Mosunetuzumab

A T-cell–engaging bispecific antibody being developed across lymphoma

A T-cell–engaging bispecific antibody, mosunetuzumab is designed to bind to CD3 on T cells and binds monovalently to CD20 on B cells, inducing lysis of target B cells^1,2

CD=cluster of differentiation.